OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways

Toxicology and Applied Pharmacology

Volumn 272, Issue 3, 2013, Pages 616-624

  Omar, Hany A ^a,b   Arafa, El Shaimaa A ^b   Salama, Samir A ^c   Arab, Hany H ^d   Wu, Chieh Hsi ^e   Weng, Jing Ru ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b Beni Suef University   (Egypt)

^c Al Azhar University   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Akt NF B; Angiogenesis; MAPKs; MMP 2; OSU A9; VEGF

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; [1 (4 CHLORO 3 NITROBENZENESULFONYL) 1H INDOL 3 YL] METHANOL; ANGIOGENESIS INHIBITOR; BETA ACTIN; DIMETHYL SULFOXIDE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; MATRIX METALLOPROTEINASE; METHANOL DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RETINOIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHORIOALLANTOIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NEOVASCULARIZATION (PATHOLOGY); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ZYMOGRAPHY;

4′,6-DIAMIDINO-2-PHENYLINDOLE; [3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYL-2H-TETRAZOLIUM BROMIDE]; AKT-NF-ΚB; ANGIOGENESIS; CAM; CHORIOALLANTOIC MEMBRANE; DAPI; DIMETHYL SULFOXIDE; DMSO; EGM-2; ENDOTHELIAL CELL GROWTH MEDIUM-2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUVECS; MAPKS; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MMP-2; MMPS; MTT; NF-ΚB; NUCLEAR FACTOR-KAPPA B; OSU-A9; PARP; POLY (ADP-RIBOSE) POLYMERASE; RA; RETINOIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL SURVIVAL; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; METHANOL; NF-KAPPA B; ONCOGENE PROTEIN V-AKT;

EID: 84884722125     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.07.014     Document Type: Article

References (43)

1. Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 2010, 13:16-28.
2. Arafa el S.A., Zhu Q., Shah Z.I., Wani G., Barakat B.M., Racoma I., El-Mahdy M.A., Wani A.A. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat. Res. 2011, 706:28-35.
3. Artacho-Cordon F., Rios-Arrabal S., Lara P.C., Artacho-Cordon A., Calvente I., Nunez M.I. Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. Surg. Oncol. 2012, 21:e143-e151.
4. Bai L.Y., Omar H.A., Chiu C.F., Chi Z.P., Hu J.L., Weng J.R. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother. Pharmacol. 2011, 68:489-496.
5. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
6. Byrne A.M., Bouchier-Hayes D.J., Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med. 2005, 9:777-794.
7. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
8. Chabut D., Fischer A.M., Colliec-Jouault S., Laurendeau I., Matou S., Le Bonniec B., Helley D. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression. Mol. Pharmacol. 2003, 64:696-702.
9. Cheung A.K., Ko J.M., Lung H.L., Chan K.W., Stanbridge E.J., Zabarovsky E., Tokino T., Kashima L., Suzuki T., Kwong D.L., Chua D., Tsao S.W., Lung M.L. Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8390-8395.
10. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
11. Dell'Eva R., Ambrosini C., Vannini N., Piaggio G., Albini A., Ferrari N. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer 2007, 110:2007-2011.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
13. Hung W.C., Chang H.C. Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells. J. Agric. Food Chem. 2009, 57:76-82.
14. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
15. Khurana R., Simons M., Martin J.F., Zachary I.C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005, 112:1813-1824.
16. Kitamura T., Asai N., Enomoto A., Maeda K., Kato T., Ishida M., Jiang P., Watanabe T., Usukura J., Kondo T., Costantini F., Murohara T., Takahashi M. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat. Cell Biol. 2008, 10:329-337.
17. Klein G., Vellenga E., Fraaije M.W., Kamps W.A., de Bont E.S. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 2004, 50:87-100.
18. Kulp S.K., Chen C.S., Wang D.S., Chen C.Y. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin. Cancer Res. 2006, 12:5199-5206.
19. Liekens S., Bronckaers A., Hernandez A.I., Priego E.M., Casanova E., Camarasa M.J., Perez-Perez M.J., Balzarini J. 5'-O-tritylated nucleoside derivatives: inhibition of thymidine phosphorylase and angiogenesis. Mol. Pharmacol. 2006, 70:501-509.
20. Morais C., Gobe G., Johnson D.W., Healy H. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis 2009, 12:365-379.
21. Nacev B.A., Liu J.O. Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole. PLoS One 2011, 6:e24793-e24802.
22. Omar H.A., Sargeant A.M., Weng J.R., Wang D., Kulp S.K., Patel T., Chen C.S. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol. Pharmacol. 2009, 76:957-968.
23. Omar H.A., Berman-Booty L., Weng J.R. Energy restriction: stepping stones towards cancer therapy. Future Oncol. 2012, 8:1503-1506.
24. Reddy A.S., Zhang S. Polypharmacology: drug discovery for the future. Expert. Rev. Clin. Pharmacol. 2013, 6:41-47.
25. Roomi M.W., Monterrey J.C., Kalinovsky T., Rath M., Niedzwiecki A. In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol. Rep. 2010, 23:605-614.
26. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
27. Schram K., De Girolamo S., Madani S., Munoz D., Thong F., Sweeney G. Leptin regulates MMP-2, TIMP-1 and collagen synthesis via p38 MAPK in HL-1 murine cardiomyocytes. Cell. Mol. Biol. Lett. 2010, 15:551-563.
28. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90:1243-1250.
29. Singh R.P., Dhanalakshmi S., Agarwal C., Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005, 24:1188-1202.
30. Szinwong M., Sidek S.M., Mahmud R., Stanslas J. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Clin. Exp. Pharmacol. Physiol. 2013, 40:307-319.
31. Tammali R., Reddy A.B., Srivastava S.K., Ramana K.V. Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 2011, 14:209-221.
32. Tang J.Y., Li S., Li Z.H., Zhang Z.J., Hu G., Cheang L.C., Alex D., Hoi M.P., Kwan Y.W., Chan S.W., Leung G.P., Lee S.M. Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One 2010, 5:e11822-e11835.
33. Tate C.M., Blosser W., Wyss L., Evans G., Xue Q., Pan Y., Stancato L. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J. Biol. Chem. 2013, 288:6743-6753.
34. Waas E.T., Lomme R.M., DeGroot J., Wobbes T., Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br. J. Cancer 2002, 86:1876-1883.
35. Wang M., Wang T., Liu S., Yoshida D., Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2003, 20:65-72.
36. Wang X.Y., Ju S., Li C., Peng X.G., Chen A.F., Mao H., Teng G.J. Non-invasive imaging of endothelial progenitor cells in tumor neovascularization using a novel dual-modality paramagnetic/near-infrared fluorescence probe. PLoS One 2012, 7:e50575-e50586.
37. Weng J.R., Tsai C.H., Kulp S.K., Wang D., Lin C.H., Yang H.C., Ma Y., Sargeant A., Chiu C.F., Tsai M.H., Chen C.S. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res. 2007, 67:7815-7824.
38. Weng J.R., Tsai C.H., Omar H.A., Sargeant A.M., Wang D., Kulp S.K., Shapiro C.L., Chen C.S. OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling. Carcinogenesis 2009, 30:1702-1709.
39. Weng J.R., Bai L.Y., Omar H.A., Sargeant A.M., Yeh C.T., Chen Y.Y., Tsai M.H., Chiu C.F. A novel indole-3-carbinol derivative inhibits the growth of human oral squamous cell carcinoma in vitro. Oral Oncol. 2010, 46:748-754.
40. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7:3129-3140.
41. Wu L.W., Mayo L.D., Dunbar J.D., Kessler K.M., Baerwald M.R., Jaffe E.A., Wang D., Warren R.S., Donner D.B. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J. Biol. Chem. 2000, 275:5096-5103.
42. Wu G., Luo J., Rana J.S., Laham R., Sellke F.W., Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc. Res. 2006, 69:512-519.
43. Yue P., Gao Z.H., Xue X., Cui S.X., Zhao C.R., Yuan Y., Yin Z., Inagaki Y., Kokudo N., Tang W., Qu X.J. Des-gamma-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway. Eur. J. Cancer 2011, 47:1115-1124.